Literature DB >> 16360411

Expression of survivin, p53, and caspase 3 in Barrett's esophagus carcinogenesis.

Anna Parenti1, Genesio Leo, Andrea Porzionato, Giovanni Zaninotto, Antonio Rosato, Vito Ninfo.   

Abstract

The regulation of apoptosis, as a distinctive form of programmed cell death, in multistep Barrett's esophagus (BE) carcinogenesis is poorly understood. The aim of this study was to investigate, in the intestinal metaplasia-dysplasia-carcinoma sequence, the role of survivin, an inhibitor of apoptosis; the p53 protein, a tumor suppressor gene involved in cell cycle control; and caspase 3, a protease-inducing apoptosis and inhibited by survivin. Immunohistochemical expression was tested in 40 cases of BE, including 11 low-grade and 19 high-grade dysplasias (HGD), and samples were obtained from 40 surgical specimens of esophagectomy performed for HGD or Barrett's adenocarcinoma. To define the deregulation time of the proteins, overexpression was evaluated in relation to the proliferative and/or maturative compartment. In BE, cytoplasmic expression of survivin and caspase 3 (100% of cases) was significantly higher than expression of p53 (25%). The latter increased with increasing grade of dysplasia. In BE, the expression of survivin, p53, and caspase 3 mainly involved the proliferative compartment, whereas in LGD and HGD, the 3 proteins were coexpressed in both proliferative and maturative compartments. These results indicate that survivin overexpression is an early event in the proliferative compartment of BE, preceding both p53 accumulation and dysplastic changes. Cytoplasmic survivin location may indicate an initial antiapoptotic, more than proliferative, role in the early phases of Barrett carcinogenesis. Expression of caspase 3 in BE and dysplasia may be ascribed to accumulation of the nonactivated form, as the antibody used detects both cleaved and uncleaved caspase 3.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16360411     DOI: 10.1016/j.humpath.2005.10.003

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

1.  The RNA-binding protein CUG-BP1 increases survivin expression in oesophageal cancer cells through enhanced mRNA stability.

Authors:  Elizabeth T Chang; James M Donahue; Lan Xiao; Yuhong Cui; Jaladanki N Rao; Douglas J Turner; William S Twaddell; Jian-Ying Wang; Richard J Battafarano
Journal:  Biochem J       Date:  2012-08-15       Impact factor: 3.857

2.  Expression of p16 and Survivin in gliomas and their correlation with cell proliferation.

Authors:  Yansheng Gao; Lingzhen Li; Laijun Song
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

Review 3.  Prognostic value of Caspase-3 expression in cancers of digestive tract: a meta-analysis and systematic review.

Authors:  Hao Chen; Xia Yang; Zhenbo Feng; Ruixue Tang; Fanghui Ren; Kanglai Wei; Gang Chen
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 4.  Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma.

Authors:  R C Fitzgerald
Journal:  Gut       Date:  2006-12       Impact factor: 23.059

Review 5.  Implication of Gastric Cancer Molecular Genetic Markers in Surgical Practice.

Authors:  Marina V Nemtsova; Vladimir V Strelnikov; Alexander S Tanas; Igor I Bykov; Dmitry V Zaletaev; Viktoria V Rudenko; Alexander I Glukhov; Tatiana V Kchorobrich; Yi Li; Vadim V Tarasov; George E Barreto; Gjumrakch Aliev
Journal:  Curr Genomics       Date:  2017-10       Impact factor: 2.236

Review 6.  Impact of Environmental and Pharmacologic Changes on the Upper Gastrointestinal Microbiome.

Authors:  Joshua Bilello; Ikenna Okereke
Journal:  Biomedicines       Date:  2021-05-29

7.  Expression of survivin and p53 in oral lichen planus, lichenoid reaction and lichenoid dysplasia: An immunohistochemical study.

Authors:  Shaini Basheer; P M Shameena; S Sudha; Sujatha Varma; S Vidyanath; Aniruddha Varekar
Journal:  J Oral Maxillofac Pathol       Date:  2017 Sep-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.